John Chiminski, Catalent (JPM20)
Catalent snaps up Promethera's cell therapy subsidiary, complete with a Belgian plant to help scale plasmid DNA efforts
Riding a wave from its work on the Covid-19 response, CDMO giant Catalent has been expanding rapidly in next-gen cell therapies as it gets prepped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
